Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKF95S
|
|||
| Drug Name |
BNT113
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42; ICD-9: 199] | Phase 2 | [1] | |
| Company |
BioNTech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04534205) An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.